Eva Casal Mendez, PhD
About Eva Casal Mendez, PhD
Eva Casal Mendez, PhD, is the Global Commercial Lead IMiD Portfolio, Hematology at Bristol Myers Squibb in the United States. She has extensive experience in the pharmaceutical industry, particularly in hematology-oncology and immunotherapy, with a strong background in biochemistry and strategic leadership.
Title and Current Role
Eva Casal Mendez, PhD, holds the title of Global Commercial Lead IMiD Portfolio, Hematology at Bristol Myers Squibb. Based in the United States, she is responsible for the commercial strategy and operations related to hematology products.
Previous Experience at Celgene
Eva Casal Mendez's career at Celgene includes multiple senior roles. She was the Global Medical Director for Multiple Myeloma Immunotherapy Pipeline, overseeing the launch of Abecma (CAR T) from 2018 to 2020. Before this, she was the Associate Director & Medical Launch Lead for Pomalyst in Global Medical Affairs from 2017 to 2018. She also worked as the Senior Manager of Strategy & Commercial Operations for EMEA from 2013 to 2017 in Switzerland.
Experience in Consulting
Before her tenure at Celgene, Eva Casal Mendez worked extensively in consulting roles. She served as a Senior Consultant at IMS Health from 2008 to 2013, and as an Associate Consultant at OC&C Strategy Consultants from 2006 to 2008. Early in her career, she completed an internship at Roche Pharmaceuticals from 1999 to 2000.
Education and Leadership Programs
Eva Casal Mendez has an impressive educational background. She attended Harvard Business School, where she completed the High Potentials Leadership Program in 2019. She earned her PhD in Biochemistry as a Gates Scholar at the University of Cambridge, studying there from 2001 to 2005. Additionally, she holds a 1st class BSc in Biochemistry with a Year in Industry from Imperial College London, completed from 1997 to 2001.
Leadership in Hematology and Commercial Strategy
At Bristol Myers Squibb and previously at Celgene, Eva Casal Mendez has led the global strategy and life cycle management for key hematology brands including Revlimid, Pomalyst, and Empliciti. These brands collectively achieved over $15 billion in sales and experienced double-digit growth in 2020. Her role involves working with cross-functional teams to achieve strategic objectives in the pharmaceutical industry.